ASCO
Opdivo-Yervoy Before Tafinlar-Mekinist Provides Optimal Benefit to BRAF-Mutant Melanoma Patients
Premium
The Phase III DREAMseq trial pinpointed these patients' best treatment sequence, but questions linger about anti-PD-1 monotherapy and emerging treatments.Â
Real-World Data from OneOncology, Roche Shed Light on NSCLC NGS Trends in Community Practices
Premium
The percentage of NSCLC patients undergoing biomarker testing has increased in recent years, but turnaround time and socioeconomic disparities need addressing.
Strata Oncology Developing Integrated TMB, PD-L1, PD-L2 Test to Predict Checkpoint Inhibitor Benefit
Premium
The diagnostic company is confirming initial findings in a validation study and exploring companion diagnostic partnerships for the investigational test.
ASCO Updates Guideline Recommending Adjuvant Lynparza for BRCA1/2-Mutated Early Breast Cancer
The guideline comes in the wake of the OlympiA trial results, which showed that the PARP inhibitor significantly improved invasive disease-free survival.
Lifileucel's BLA is again delayed, but a 33-month update from a pivotal melanoma trial, along with early data from a frontline study, show continued potential.